Psychiatric Adverse Events: Navigating a New Drug Safety Landmine
This article was originally published in RPM Report
Executive Summary
Psychiatric drug safety isn't just about antidepressants any more. An increased risk of depression and suicidality is killing new drug prospects and has threatened multi-billion dollar franchises. FDA aims to help by injecting some clarity and predictability into the process. Now It's up to sponsors to take advantage of ithe FDA's initiatives.
You may also be interested in...
The Billion Dollar REMS: Xenazine and the Value of Facing Regulatory Realities
Prestwick's Huntington's chorea therapy won FDA approval in August, triggering a flurry of deals valued at over $1 billion. Not bad for a 50-year-old drug expected to treat no more than 5,000 patients-and a powerful case study in how embracing the new regulatory realities can pay off.
The Billion Dollar REMS: Xenazine and the Value of Facing Regulatory Realities
Prestwick's Huntington's chorea therapy won FDA approval in August, triggering a flurry of deals valued at over $1 billion. Not bad for a 50-year-old drug expected to treat no more than 5,000 patients-and a powerful case study in how embracing the new regulatory realities can pay off.
The Impact of FDAAA On Drug Approvals: Setting the Baseline
An analysis of the first six months of the new era in drug regulation shows that FDA is enthusiastically and creatively applying its new drug safety tools. Biopharma companies will be watching carefully to see how the metrics of the FDAAA era move over time.